Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
Open Access
- 17 April 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Musculoskeletal Disorders
- Vol. 9 (1), 52
- https://doi.org/10.1186/1471-2474-9-52
Abstract
To analyse available evidence on the efficacy and safety of anti-TNFα drugs (infliximab, etanercept and adalimumab) for treating rheumatoid arthritis (RA).This publication has 73 references indexed in Scilit:
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table 1Annals Of The Rheumatic Diseases, 2013
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- Thoracic high resolution computed tomography in patients with ankylosing spondylitis and without respiratory symptomsAnnals Of The Rheumatic Diseases, 2003
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002
- The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- An Assessment of Clinically Useful Measures of the Consequences of TreatmentThe New England Journal of Medicine, 1988
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988